عرض تفاصيل البحث

ادناه جميع التفاصيل الخاصة بالبحث المطلوب عرضه. توفر هذه المنصة معلومات اساسية حول البحث, لمزيد من التفاصيل يرجى متابعة التصفح من خلال الضغط على الرابط الاصلي للبحث او رابط DOI.

عنوان البحث
Serum Myeloperoxidase As A Biomarker Of Asthma Severity Among Adults: A Case Control Study
عنوان المجلة
Reports Of Biochemistry And Molecular Biology
ISSN-23223480
تفاصيل النشر
سنة النشر - 2022 / الفهرس الاصلي للمجلة - 11 : 1 (عدد الصفحات 7)
تصنيف البحث
الطب - المجموعة الطبية
رابط DOI
#
رابط البحث
فتح في موقع المجلة الرسمي
البحث والاستدامة
الهدف 3 – الصحة الجيدة والرفاه   المزيد حول هذا الهدف
البحث والمجتمع
نعم , يدعم
الكلمات المفتاحية
Asthma, And Neutrophils, FEV1, MPO, PEF

اسم الباحثجهة الانتساببلد الباحث
حيدر عبد الامير مكي كلية الصيدلة العراق
مازن جعفر موسى كلية الصيدلة العراق
سهاد حافض كلية الصيدلة العراق
صفا جهاد كلية الصيدلة العراق

Background: The contribution of neutrophils is still indistinct in the inflammatory response of bronchial asthma (BAs). Myeloperoxidase (MPO) is an enzyme released from the primary azurophilic granules of the neutrophils. The study aimed to evaluate the levels of serum MPO as a biomarker for the assessment of the level of asthma control. Methods: The study participants included 94 asthmatic patients and 86 healthy controls. The identification of asthma severity had assessed using the Global Initiative for Asthma guidelines . Asthmatic adults had divided into three groups: Good (n= 22), partial (n= 30), and poor control (n= 44). Also, patients have been divided again into two groups (treated and untreated) for BAs. Results: The predicted FEV1% and the peak expiratory flow (PEF/L) of all participants had verified by spirometry. The mean patients’ age was 31.9±15.1 year, with a predominance of females. The mean asthma duration was 10.5±8.6 years. Mean spirometric parameters (FEV1 and PEF) were significantly lower among the patients (0.00). Significant higher MPO levels had observed among BAs patients (p-0.00). The MPO levels have not differed significantly with asthma levels and had significant differences with the history of treatment. There was a nonsignificant negative correlation between the mean MPO levels and the spirometry variables among the patients. ROC curves revealed a sensitivity, specificity, accuracy for MPO (80.9%, 72.1%, and 84.3%), respectively to predict asthmatic severity. Conclusion: There were significantly higher MPO levels compared to healthy controls. Levels of serum MPO had a non-significant positive correlation with levels of asthma control, but a negative non-significant correlation with spirometric results.